Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a phase 2 study for people with systemic lupus erythematosus (SLE) in 2025.
The first drug of its kind to advance into clinical development, VENT-03 is an oral therapy designed to target and inhibit cGAS, a cell receptor linked to lupus and a broad range of other autoimmune diseases. The phase 1 trial examined pharmacokinetics , target engagement, safety and tolerability in 72 healthy adult volunteers. The results showed that VENT-03 was safe and well-tolerated at all tested dose levels with all treatment-related adverse events being mild and easily managed. VENT-03 exhibited a favorable pharmacokinetic profile, supporting once-daily dosing. Additionally, VENT-03 achieved plasma concentrations necessary for complete target inhibition and demonstrated strong pharmacodynamic (what a drug does to the body) effects.
Continue to follow the Lupus Foundation of America for updates lupus drug developments and clinical trials. Learn more about medications used to treat lupus.
This post was originally published on this site